Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects

详细信息    查看全文

• 作者：Julien P. N. Papillon ; Changgang Lou ; Alok K. Singh ; Christopher M. Adams ; Gary M. Ksander ; Michael E. Beil ; Wei Chen ; Jennifer Leung-Chu ; Fumin Fu ; Lu Gan ; Chii-Whei Hu ; Arco Y. Jeng ; Daniel LaSala ; Guiqing Liang ; Dean F. Rigel ; Kerry S. Russell ; John A. Vest ; Catherine Watson
• 刊名：Journal of Medicinal Chemistry
• 出版年：2015
• 出版时间：December 10, 2015
• 年：2015
• 卷：58
• 期：23
• 页码：9382-9394
• 全文大小：575K
• ISSN：1520-4804

文摘

Human clinical studies conducted with LCI699 established aldosterone synthase (CYP11B2) inhibition as a promising novel mechanism to lower arterial blood pressure. However, LCI699鈥檚 low CYP11B1/CYP11B2 selectivity resulted in blunting of adrenocorticotropic hormone-stimulated cortisol secretion. This property of LCI699 prompted its development in Cushing鈥檚 disease, but limited more extensive clinical studies in hypertensive populations, and provided an impetus for the search for cortisol-sparing CYP11B2 inhibitors. This paper summarizes the discovery, pharmacokinetics, and pharmacodynamic data in preclinical species and human subjects of the selective CYP11B2 inhibitor 8.